Daunorubicin, Cytarabine, and Nilotinib for Newly Diagnosed AML With KIT Expression
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression
Am. J. Hematol 2023 Jan 09;[EPub Ahead of Print], A Al-Kali, R Tibes, P Atherton, J Palmer, HB Alkhateeb, M Patnaik, K Begna, N Gangat, S Hashmi, R He, M LitzowFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.